Skip to content

VX-548

DRUG11 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Acute PainPainPainful Lumbosacral Radiculopathy

Phase 1

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548
CompletedNCT05455502
Vertex Pharmaceuticals IncorporatedPain
Start: 2022-07-13End: 2022-09-17Updated: 2024-03-20
A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin
CompletedNCT05541471
Vertex Pharmaceuticals IncorporatedPain
Start: 2022-09-22End: 2023-04-28Updated: 2024-03-20
Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment
CompletedNCT05560464
Vertex Pharmaceuticals IncorporatedPain
Start: 2022-10-14End: 2023-07-24Updated: 2024-03-20
Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants
CompletedNCT05635110
Vertex Pharmaceuticals IncorporatedPain
Start: 2022-12-15End: 2023-06-08Updated: 2024-03-20
Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment
CompletedNCT05704556
Vertex Pharmaceuticals IncorporatedPain
Start: 2023-02-27End: 2024-03-30Updated: 2024-04-29
A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
CompletedNCT05818852
Vertex Pharmaceuticals IncorporatedPain
Start: 2023-04-12End: 2023-06-28Updated: 2024-03-20
A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548
CompletedNCT05851157
Vertex Pharmaceuticals IncorporatedPain
Start: 2023-05-03End: 2023-11-08Updated: 2024-03-20
A Microneurography Study of NaV1.8 Inhibition in Healthy Adults
CompletedNCT06420765
Vertex Pharmaceuticals IncorporatedPain
Start: 2024-05-21End: 2025-04-04Updated: 2025-04-20

Phase 2

Related Papers

New England Journal of Medicine2023-08-02216 citations